<DOC>
	<DOCNO>NCT01598415</DOCNO>
	<brief_summary>Study objective : - Part 1 TDU11685 To assess patient knee Osteoarthritis ( OA ) , safety , tolerability pharmacokinetics ( PK ) single intra-articular dos SAR113945 . - Part 2 ACT12505 To assess patient knee OA , efficacy , safety tolerability single intra-articular dose SAR113945 .</brief_summary>
	<brief_title>Safety Single Doses SAR113945 Efficacy Safety New Formulation Given Into Knee Osteoarthritis Patients / Part II</brief_title>
	<detailed_description>- Screening perform within 28 day dose . Following single dose study medication , study period patient 168 day .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion criterion : Diagnosis primary knee osteoarthritis , base upon follow : Xray Magnetic Resonance Imaging ( MRI ) evidence within last 6 month joint space narrow osteophyte formation Patients Kellgren Lawrence classification II/III , total Western Ontario McMaster ( WOMAC ) score 24 72 . Patients fulfil American College Rheumatology Clinical Radiographic criterion Osteoarthritis . Exclusion criterion : Patients young 40 year Women child bear potential . Women either sterilize 3 month , postmenopausal 12 month . Menopause define age 60 year amenorrheic least 2 year plasma FSH level &gt; 30 IU/L . Secondary osteoarthritis : e.g. , autoimmune disease , joint dysplasia , aseptic osteonecrosis , acromegaly , Paget 's disease , EhlersDanlos Syndrome , Gaucher 's disease , Stickler 's syndrome , joint infection , haemophilia , haemochromatosis , calcium pyrophosphate deposition disease , neuropathic arthropathy . Presence local skin abnormality affect knee joint . Intraarticular injection within 3 month . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>